Skip to main content
Premium Trial:

Request an Annual Quote

Sequitur, BMS Expand Collaboration to Include RNAi

NEW YORK, March 3 - Sequitur said today that it has expanded an existing agreement with Bristol-Myers Squibb to include work with RNAi.


Sequitur said it is now entering the fourth year of the existing collaboration, under which it has been performing biological screening assays for target validation. Under the expanded agreement, the company will also provide BMS with RNAi -- a form of double-stranded RNA that causes sequence-specific inhibition of target mRNAs -- for use in target validation studies.


In January 2001, Sequitur agreed to provide BMS with antisense compounds for target validation.


Sequitur's other clients include Incyte Genomics, GlaxoSmithKline, Pfizer, Genentech, Procter and Gamble, Harvard University, the Mayo Clinic, Scripps, Roche, Schering-Plough, and Wyeth.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.